Other

Csl Limited

The University of New South Wales

Massachusetts Institute of Technology

The Univ. of New South Wales

Adrian Lee

Christopher Vincent Doidge

Stuart L Hazell

Flona J Radcliff

Elizabeth Ann Webb

Ian George Barr

Michael John Kleinig

Fiona Jane Buck

Charles Alexander Quinn

Dianna Margaret Hocking

David Schauer

Fiona Jane Radcliff

Mark Whary

Fona J Radcliff

Elizabeth Pietrzykowski

James J Fox

Protective Helicobacter antigens, especially H. pylori antigens, and the use of these antigens for the treatment of or prevention of, gastroduodenal disease associated with H. pylori infection.

Protective helicobacter antigens

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS of or , or an immunogenic fragment thereof.

Antigenic preparation for treatment or prevention of helicobacter infection

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacteria, particularly the catalase enzyme of or , or an immunogenic fragment thereof.

Treatment and prevention of helicobacter infection

The treatment of IBD in mammals, including humans, is described. More particularly, the present invention relates to compositions and methods for the treatment of IBD associated with Helicobacter or other bacterial infections in mammals, including humans, and to vaccine compositions and antibodies suitable for use in such treatment.

Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease

An antigenic preparation for use in the treatment of prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacterial, particularly the catalase enzyme of or , or an immunogenic fragment thereof.

The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one or more Heliobacter antigen(s), optionally in association with a mucosal adjuvant.

Treatment of H. pylori associated gastroduodenal disease

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacteria, particularly the catalase enzyme of H. pylori or H. felis, or an immunogenic fragment thereof.

Growing community of inventors

Lane Cove, Australia

Adrian Lee